ELGAN Pharma

ELGAN Pharma Overview

ELGAN Pharma is a clinical-stage neonatology-focused biotechnology company developing safe, tailored therapies to address medical problems and developmental difficulties common in babies born very early. The company has two leading clinical programs: ELGN-GI and ELGN-EYE. Both therapies address high unmet medical needs of preterm infants with no existing solutions to date. ELGN-GI promotes a faster maturation of an infant’s intestines, allowing them to rapidly reach full enteral feeding and become independent from parenteral nutrition while minimizing serious complications and reducing burden and costs to healthcare systems. The product has completed several clinical trials, including a successful phase 3, and is currently starting a second phase 2. ELGN-EYE is a local drug targeted at preventing vision impairment due to retinopathy of prematurity (ROP), a condition caused by the underdeveloped blood vessels in the eyes of premature babies at the time of birth. ROP is the leading cause of blindness in children worldwide. A phase 1 study of the product was successfully concluded and a phase 2 is currently launching.

Cumulative Funding Raised Over Time ($)

Latest News

Jun 5, 2025 · www.prnewswire.com

growth-positive

/PRNewswire/ -- Elgan Pharma Ltd. and Chiesi Farmaceutici S.p.A today announced the dosing of the first participating infants in FIT-PIV, a Phase 3 clinical...

Elgan Pharma and Chiesi Farmaceutici S.p.A have announced the commencement of a Phase 3 clinical trial for ELGN-2112, a novel treatment for intestinal malabsorption in preterm infants. This collaboration aims to address the unique medical needs of premature infants by improving gastrointestinal function and reducing the need for intravenous feeding. The FIT-PIV study will enroll 420 infants across multiple international sites, focusing on achieving full enteral feeding earlier to reduce complications. The partnership highlights both companies commitment to advancing neonatal care through innovative therapeutic solutions.

Product StagePartners

Jul 19, 2023 · nocamels.com

growth-positive

Startup Treating Newborns In Serious Condition Raises $2.5M

Israeli biopharma company, ELGAN Pharma, has been awarded a $2.5 million grant by the European Innovation Council (EIC). The company is developing an oral formula for the treatment of intestinal malabsorption, a digestive disorder that prevents preterm infants from absorbing nutrients from feeding. The grant will help ELGAN embark on a clinical study to further prove the safety and efficacy of its treatment. ELGAN Pharma was founded in 2018, and is based in Nazareth, northern Israel.

Investment

Mar 2, 2022 · www.prnewswire.com

growth-positive

Elgan Pharma Announces Positive Results from its Phase III Study of ELGN-GI in Preterm Infants for Treatment of Intestinal Malabsorption

Elgan Pharma, a clinical biopharmaceutical company, announced positive results from a Phase III study of their proprietary enteral insulin formulation, ELGN-GI, for the treatment of intestinal malabsorption in preterm infants. The study showed significant improvements in gastrointestinal function and a reduction in related complications. The company plans to initiate a second Phase III trial for ELGN-GI later in 2022. Elgan Pharma also mentioned their plans to launch a Phase IIb clinical trial for their second product candidate, ELGN-EYE, for the treatment of retinopathy of prematurity. The company aims to develop therapies for the unmet medical needs of premature infants. The Phase III study enrolled 303 infants across multiple sites. No specific partners or customers were mentioned in the article.

CustomersInvestment

Mar 2, 2022 · www.jpost.com

growth-positive

https://www.jpost.com/health-and-wellness/pregnancy-and-birth/article-699123

Elgan Pharma has announced the success of its ELGN-GI insulin formulation in improving the early lives of premature babies. The formulation, tailored for newborns, helps infants with feeding intolerance caused by intestinal malabsorption. It improves gastrointestinal function, reduces complications, and decreases the need for intravenous feeding. The use of ELGN-GI led to significant improvements in gastrointestinal function and a decrease in hospital stay. Elgan Pharma plans to initiate a second Phase III trial for ELGN-GI in 2022. The company is also working on a treatment for retinopathy of prematurity. The success of ELGN-GI positions Elgan Pharma as a pioneer in developing therapies for the unique medical needs of premature infants.

Customers

May 6, 2021 · isotopia-global.com

growth-positive

Elgan Pharma& Isotopia Molecular Imaging Signed a Strategic agreement

Isotopia and Elgan Pharma have entered into a partnership agreement. Isotopias capabilities in sterile production and compliance with good manufacturing practices (cGMP) will support Elgans transition to GMP production for Phase III and commercial scale. Isotopia will provide resources for successful clinical trials and marketing authorization application (MAA) filing. Isotopia is a collaboration between The Metrontario Group and Israeli scientists in the field of radiopharmaceuticals and sterile manufacturing. Elgan Pharma is a biotechnology company focused on neonatology, developing therapies for premature infants. The partnership aims to deliver breakthrough therapies to premature infants and improve outcomes for Extremely Low Gestational Age Newborns (ELGANs).

Partners

Funding

Team Members

3

Employees: 11-50

Web & Social Links

Locations

Wadi el-Haj Street 13, Nazareth, Israel

Photos & Videos

No files yet

ELGAN Pharma Internal

Recent Updates

No update log entries.

Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.

Admin Info